This company listing is no longer active
CinCor Pharma Management
Management criteria checks 0/4
Key information
Marc M. de Garidel
Chief executive officer
US$9.6m
Total compensation
| CEO salary percentage | 2.6% |
| CEO tenure | 1.6yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.5yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About CinCor Pharma's (NASDAQ:CINC) Cash Burn Situation
Nov 06
CinCor Pharma prices upsized stock and pre-funded warrants offering
Aug 11CinCor Pharma says last patient randomized in phase 2 trial for baxdrostat to treat hypertension
Jul 26We Think CinCor Pharma (NASDAQ:CINC) Can Afford To Drive Business Growth
Jul 23We're Hopeful That CinCor Pharma (NASDAQ:CINC) Will Use Its Cash Wisely
Apr 08CinCor: 2022 Data Catalysts Will Derisk The Stock
Apr 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$88m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$61m |
| Dec 31 2021 | US$10m | US$250k | -US$50m |
Compensation vs Market: Marc M.'s total compensation ($USD9.58M) is above average for companies of similar size in the US market ($USD5.37M).
Compensation vs Earnings: Insufficient data to compare Marc M.'s compensation with company performance.
CEO
Marc M. de Garidel (64 yo)
1.6yrs
Tenure
US$9,584,721
Compensation
Mr. Marc M. P. de Garidel has been the Chief Executive Officer of CinCor Pharma, Inc. since July 2021 and has been its Director since May 2021. Mr. de Garidel was Chief Executive Officer of Corvidia Therap...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.6yrs | US$9.58m | 0.029% $ 363.2k | |
| Chief Medical Officer | 1.5yrs | US$2.07m | 0.0059% $ 75.5k | |
| Co-Founder & COO | 5.1yrs | US$194.26k | 0.32% $ 4.1m | |
| Executive VP | less than a year | no data | no data | |
| Senior VP and Head of People | less than a year | no data | no data | |
| Corporate Controller | no data | no data | no data |
1.5yrs
Average Tenure
57.5yo
Average Age
Experienced Management: CINC's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$9.58m | 0.029% $ 363.2k | |
| Independent Chairman of the Board | 3.8yrs | US$194.59k | 0.067% $ 854.6k | |
| Independent Director | 1.8yrs | US$600.37k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.8yrs | US$600.37k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.8yrs | no data | no data | |
| Independent Director | 3.8yrs | US$194.59k | 0% $ 0 | |
| Independent Director | 1.1yrs | no data | no data | |
| Independent Director | 1.4yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
1.8yrs
Average Tenure
57yo
Average Age
Experienced Board: CINC's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/25 10:49 |
| End of Day Share Price | 2023/02/23 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CinCor Pharma, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael DiFiore | Evercore ISI |
| Madhu Kumar | Goldman Sachs |
| Yuchen Ding | Jefferies LLC |